Elon Musk’s company Neuralink announced Thursday that it received approval from the Food and Drug Administration (FDA) to conduct its first-in-human clinical study.

"We are excited to share that we have received the FDA’s approval to launch our first-in-human clinical study," the company said in a tweet.

Musk helped co-found Neuralink, a neurotechnology company working to develop brain implants that could someday help people who are paralyzed walk again, as well as help with other neurological issues.

Neuralink has announced that the U.S. Food and Drug Administration (FDA) has approved the launch of its first clinical study in humans.

"We are excited to share that we have received the FDA’s approval to launch our first-in-human clinical study!" Neuralink's official Twitter account wrote on Thursday.(opens in a new tab) "This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people."

In December 2022, founder Elon Musk gave an update on his other, other company, the brain implant startup Neuralink. As early as 2020, the company had been saying it was close to starting clinical trials of the implants, but the December update suggested those were still six months away. This time, it seems that the company was correct, as it now claims that the Food and Drug Administration (FDA) has given its approval for the start of human testing.